despatch of rights issue, page-17

Very impressive indeed DH!

They look to be more switched on to - and exploitative of -Oraline's market advantages than any other distributor.

We ned these sort of 'champions'.

Clinical medical Marketing's MediScreen model is also impressive.

And they are really backing themseves. They have contracturally committed themselves to minimum Oraline orders that increase by 200% in just 2 years (from US%80,000 in 2009 to US$250,000 in 2011).

If this Mediscreen delivery model is successful here in Oz, it must have substantial potential to be grown internationally.

So the SBN/CMM partnership could have very substantial growth potential